All Skewed Up
The enormous valuation that Neoforma..com achieved in its January IPO, which followed the enormous valuation Ventro Corp. has achieved as a public company has the entire hospital supply industry buzzing. But much of the discussion has to do, plain and simple, with the phenomenal amounts of money executives at these companies have made--at least on paper--as a result of their companies' astronomical valuations.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.